24LBA Safety data from the phase 1b part of the MASTERKEY-265 study combining talimogene laherparepvec (T-VEC) and pembrolizumab for unresectable stage IIIB-IV melanoma. (September 2015) - Long, G.V.; Dummer, R.; Ribas, A.; Puzanov, I.; Michielin, O.; Vanderwalde, A.; Andtbacka, R.H.I.; Cebon, J.; Fernandez, E.; Malvehy, J.; Olszanski, A.J.; Gajewski, T.F.; et al.